VERTEX PHARMACEUTICALS INC / MA Deferred Revenue
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Deferred Revenue of $5.17 million as of 2017-12-31, per its 10-K filed 2018-02-15.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2018-02-15
- 2017-12-31: Deferred Revenue, Current $5.17M.
- 2017-09-30: Deferred Revenue, Current $13.00M.
- 2017-06-30: Deferred Revenue, Current $7.28M.
- 2017-03-31: Deferred Revenue, Current $6.06M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2017-12-31 | $5.17M 10-K · filed 2018-02-15 |
| 2017-09-30 | $13.00M 10-Q · filed 2017-10-30 |
| 2017-06-30 | $7.28M 10-Q · filed 2017-07-28 |
| 2017-03-31 | $6.06M 10-Q · filed 2017-04-28 |
| 2016-12-31 | $6.00M 10-K · filed 2018-02-15 |
| 2016-09-30 | $9.25M 10-Q · filed 2016-10-31 |
| 2016-06-30 | $11.47M 10-Q · filed 2016-08-01 |
| 2016-03-31 | $14.71M 10-Q · filed 2016-05-03 |
| 2015-12-31 | $16.30M 10-K · filed 2017-02-23 |
| 2015-09-30 | $14.00M 10-Q · filed 2015-10-30 |
| 2015-06-30 | $14.93M 10-Q · filed 2015-08-04 |
| 2015-03-31 | $15.92M 10-Q · filed 2015-05-04 |
| 2014-12-31 | $17.47M 10-K · filed 2016-02-16 |
| 2014-09-30 | $21.21M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $27.17M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $28.84M 10-Q · filed 2014-05-05 |
| 2013-12-31 | $21.51M 10-K · filed 2015-02-13 |
| 2013-09-30 | $31.01M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $32.90M 10-Q · filed 2013-08-02 |
| 2013-03-31 | $35.53M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $27.57M 10-K · filed 2014-02-11 |
| 2012-09-30 | $27.30M 10-Q · filed 2012-11-06 |
| 2012-06-30 | $27.30M 10-Q · filed 2012-08-08 |
| 2012-03-31 | $30.49M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $45.04M 10-K · filed 2013-03-01 |
| 2011-09-30 | $55.70M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $65.02M 10-Q · filed 2011-08-09 |
| 2011-03-31 | $74.19M 10-Q · filed 2011-05-06 |
| 2010-12-31 | $74.62M 10-K · filed 2012-02-22 |
| 2010-09-30 | $98.98M 10-Q · filed 2010-10-28 |
| 2010-06-30 | $78.27M 10-Q · filed 2010-08-03 |
| 2010-03-31 | $69.58M 10-Q · filed 2010-05-03 |
| 2009-12-31 | $74.96M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |